Please assess the completion status of the following clinical trial:

Trial Title: A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must satisfy the following criteria to be enrolled in the study:~Part 1, Part 2, and Part 3~1. Subject is ≥ 18 and ≤ 55 years (Part 1 and Part 2) and age is ≥ 18 and ≤ 60 years (Part 3) of age at the time of signing the ICF.~2. Subject has provided informed consent prior to initiation of any study specific activities/procedures~3. Subject has a body mass index (BMI) ≥ 18 and ≤ 30 kg/m2 (Part 1 and Part 2) and BMI ≥ 18 and ≤ 33 kg/m2 (Part 3), at screening.~4. Subject has clinical laboratory safety test results that are within normal limits or considered not clinically significant by the Investigator.~   Applicable to Part 3 only~5. Subject has a clinical diagnosis of stable plaque-type PsO at least 6 months prior to screening, defined as:~   BSA ≥ 5% (at both screening and baseline), and sPGA score ≥ 3 (at both screening and baseline)~6. Must have at least two plaques, at least 3 x 3 centimeters (cm) in diameter. One plaque will be used for punch biopsy and the other for Target Plaque Severity Score (TPSS) evaluation.~7. Must be in generally good health (except for PsO) as judged by the Investigator~8. No prior exposure to systemic treatments or biologics for the treatment of psoriasis~Exclusion Criteria:~The presence of any of the following will exclude a subject from enrollment:~Part 1, Part 2, and Part 3~1. Subject has any significant medical condition that would prevent the subject from participating in the study.~   a. Part 3 only: This exclusion does not apply to plaque psoriasis~2. History or presence of cancer~3. Presence of pre-cancerous conditions~4. History or presence of a systemic infection or any potentially opportunistic infections~5. Subject has any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~6. Subject has any condition that confounds the ability to interpret data from the study~7. Subject is pregnant or breastfeeding~8. Part 1 and Part 2 only: Subject was exposed to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or 5 half-lives of that investigational drug, if known (whichever is longer)~9. Part 1 and Part 2 only: Subject has used any prescribed systemic or topical medication within 30 days prior to the first dose administration.~10. Part 1 and Part 2 only: Subject has used any non-prescribed systemic or topical medication within 14 days prior to the first dose administration. Exceptions may apply on a case-by-case basis if considered not to interfere with the study objectives as agreed to and documented by the Investigator and Sponsor's Medical Monitor.~11. Subject has a history of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual \[DSM\]) within 2 years before the first dose administration, or positive drug screening test reflecting consumption of illicit drugs~12. Subject has a history of alcohol abuse (as defined by the current version of the DSM) within 2 years before the first dose administration, or positive alcohol screen~13. Subject is known to have a history of hepatitis B and/or hepatitis C, or have a positive result to the test for human immunodeficiency virus (HIV) antibodies at screening Note: Subjects who received hepatitis B vaccination and who test positive for hepatitis B surface antibody and negative for both hepatitis B surface antigen and hepatitis B core antibody remain eligible for study participation~14. Subject smokes \> 10 cigarettes per day, or the equivalent in other tobacco products (self-reported)~15. Vaccination within 30 days prior to the first dose administration or subject has plans to receive a vaccination during the course of the study~16. Subject has received immunization with a live or live attenuated vaccine within 2 months prior to the first dose administration or is planning to receive immunization with a live or live attenuated vaccine for 2 months following the last dose administration~17. Subject has a positive QuantiFERON®-TB Gold (or equivalent) TB test at screening or 2 successive indeterminate QuantiFERON®-TB Gold (or equivalent) TB tests at screening~18. Subject has a history of incompletely treated Mycobacterium tuberculosis (TB) infection~19. Topical therapy within 2 weeks of randomization (including, but not limited to, topical corticosteroids, retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin/dithranol). Use of phototherapy within 4 weeks prior to first dose administration.~20. Prolonged sun exposure or use of tanning booths Applicable to Part 3 only~21. Presence of non-plaque psoriasis~22. Subject has psoriasis flare within 4 weeks before screening~23. Presence of dermatological diseases other than plaque psoriasis~24. Presence of Psoriatic Arthritis~25. Use of topical therapy for psoriasis within 14 days of first dosing (including but not limited to corticosteroids, retinoids, vitamin D analog, calcineurin inhibitors, salicylic acid) Exceptions: low potency topical corticosteroids will be allowed as background therapy for treatment of psoriatic lesions of the face, axillae and groin in accordance with the manufacturers' suggested usage; subjects with scalp psoriasis will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on scalp lesions; Eucerin® cream (the standard emollient for this study; or equivalent) will also be permitted for body lesions only. Subjects must not use these treatments within 24 hours prior to each clinic visit.~26. Use of systemic therapy for psoriasis within 30 days of first dose administration~27. Use of phototherapy for psoriasis within 30 days of first dose administration~28. Use of systemic biologic treatment within 24 weeks of first dose administration~29. Exposure to an immunosuppressive or immunomodulatory drug within 30 days of first dose administration, or five half-lives of the drug (whichever is longer)~30. Exposure to an investigational drug (new chemical entity) within 30 days preceding the first dose administration, or five half-lives of that investigational drug, if known (whichever is longer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Administration of CC-92252 and Placebo in Healthy Subjects (Type: EXPERIMENTAL): Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoriasis will receive CC-92252 or placebo for up to 12 weeks.
- Administration of CC-92252 and Placebo in Psoriasis subjects (Type: EXPERIMENTAL): Part 1 of the study will be conducted as a single ascending dose study, each cohort will consist of 9 subjects. Part 2 of the study will be conducted as a multiple ascending dose study, each cohort will consist of 8 subjects. In part 3, subjects with psoris will receive CC-92252 or placebo for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy